BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23092867)

  • 1. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension.
    Swymer C; Neville MW
    Ann Pharmacother; 2012 Nov; 46(11):1506-10. PubMed ID: 23092867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
    Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
    Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
    Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
    Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
    Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tafluprost: a novel prostaglandin analog for treatment of glaucoma.
    Pantcheva MB; Seibold LK; Awadallah NS; Kahook MY
    Adv Ther; 2011 Sep; 28(9):707-15. PubMed ID: 21858491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
    Erb C; Lanzl I; Seidova SF; Kimmich F
    Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
    Oddone F; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Holló G;
    Adv Ther; 2022 Aug; 39(8):3501-3521. PubMed ID: 35524840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
    Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
    BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
    Wong TT; Aung T; Ho CL
    Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
    Uusitalo H; Pillunat LE; Ropo A;
    Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study.
    Oddone F; Tanga L; Kóthy P; Holló G;
    Adv Ther; 2020 Apr; 37(4):1436-1451. PubMed ID: 32072493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
    Hoy SM
    Drugs; 2015 Oct; 75(15):1807-13. PubMed ID: 26431840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.
    Kuwayama Y; Hashimoto M; Kakegawa R; Nomura A; Shimada F
    Adv Ther; 2017 Jun; 34(6):1411-1425. PubMed ID: 28502035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.
    Lorenz K; Pfeiffer N
    Expert Opin Pharmacother; 2014 Oct; 15(15):2255-62. PubMed ID: 25170534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.
    Garcia-Medina JJ; Benitez-Del-Castillo J; Rodríguez-Agirretxe I; Lopez-Lopez F; Moreno-Valladares A;
    J Ocul Pharmacol Ther; 2022 Apr; 38(3):252-260. PubMed ID: 35230148
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
    Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
    Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and tolerability.
    Oddone F
    Expert Opin Drug Saf; 2022 Oct; 21(10):1259-1268. PubMed ID: 36250245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension.
    Hommer A
    Drugs Today (Barc); 2010 Jun; 46(6):409-16. PubMed ID: 20571609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.